{"id":"NCT02362789","sponsor":"Novartis Pharmaceuticals","briefTitle":"Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers","officialTitle":"Exploratory Study on the Kinetics of Psoriasis Symptoms, Pruritus Intensity and Lesional Biomarkers in Patients With Moderate to Severe Plaque-type Psoriasis Treated With Subcutaneous Secukinumab (300 mg) During a 16 Week Open-label run-in Phase Followed by a 16 Week Randomized, Double-blind, Placebo-controlled Withdrawal Phase","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-01-04","primaryCompletion":"2016-07-15","completion":"2016-07-15","firstPosted":"2015-02-13","resultsPosted":"2018-12-28","lastUpdate":"2018-12-28"},"enrollment":132,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"BIOLOGICAL","name":"Secukinumab","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"Secukinumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The study is designed to explore the kinetics of psoriasis symptoms, pruritus intensity and lesional biomarkers.","primaryOutcome":{"measure":"Pruritus Intensity Visual Analogue Scale Score at Week 32","timeFrame":"Week 32","effectByArm":[{"arm":"Secukinumab","deltaMin":8.8,"sd":4.7},{"arm":"Placebo","deltaMin":27.1,"sd":4.9}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0055"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":19,"countries":["Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":130},"commonTop":["NASOPHARYNGITIS","HEADACHE","BACK PAIN","INFLUENZA","HYPERTENSION"]}}